Very recently, Bao and Colleagues provided a complete functional characterization of the mechanisms by which GFI1B and CHEK2 genetic variations affect the MPN risk through the modulation of hematopoietic stem cell function [13]. This evidence concerns the gene CHEK2 and myeloproliferative disorder.